Tumor Targeting and Imaging of Intraperitoneal Tumors by Use of Antisense Oligo-DNA Complexed with Dendrimers And/or Avidin in Mice
Overview
Authors
Affiliations
To establish an effective nonviral gene delivery and a corresponding imaging method for i.p.-disseminated tumors, various oligonucleotide-carrier complexes were synthesized, and their in vitro and in vivo properties were examined. The 20-mer multiamino-linked oligonucleotide (oligo), synthesized as antisense against the c-erbB-2 sequence, and the 3'-biotinylated form of the same oligonucleotide (oligo-Bt) were (111)In labeled through a diethylenetriaminepentaacetic acid chelate. (111)In-oligo was mixed with generation 4 polyamidoamine dendrimer (G4) or with biotinylated G4 (G4-Bt), which are positively charged to form electrostatic complexes. (111)In-oligo/G4-Bt and (111)In-oligo-Bt were conjugated to avidin ((111)In-oligo/G4-Av and (111)In-oligo-Av, respectively). (111)In-oligo/G4, (111)In-oligo/G4-Av, (111)In-oligo-Av, and carrier-free (111)In-oligo (2.96 kBq/22.4-45.9 ng of oligo) were examined for internalization in vitro in human ovarian cancer cells (SHIN3). Biodistribution of (111)In-oligo-carrier complexes or (111)In-oligo was examined in normal (n = 4-7) or i.p. SHIN3 tumor-bearing (n = 6-10) mice 2-24 h after i.p. injection (74 kBq/125-300 ng). Scintigraphy of i.p. tumor-bearing and normal mice was performed at various times postinjection of (111)In-oligo-carrier complex or (111)In-oligo (1.85 MBq/2.2 ng). (111)In-oligo-carrier complexes bound to the tumor cells were internalized at a rate of 34-56% at 24 h. In vivo, G4, G4-Av, and Av significantly enhanced tumor delivery of (111)In-oligo [9.1, 14.5, and 24.4% of injected dose per g of tissue (ID/g) at 24 h; P < 0.05, < 0.01, and < 0.0001, respectively] compared with delivery without carrier (0.8% ID/g). Scintigrams of (111)In-oligo delivered to the i.p.-disseminated tumors by the carriers were successfully obtained. In conclusion, G4, G4-Av, and Av can effectively deliver (111)In-oligo to i.p.-disseminated tumors. (111)In-oligo-carrier complexes also have potential as tracers for imaging and monitoring of gene delivery.
Development of Novel Pt-Labeled Hoechst33258: Pt Is More Suitable than In for Targeting DNA.
Obata H, Tsuji A, Kumata K, Sudo H, Minegishi K, Nagatsu K J Med Chem. 2022; 65(7):5690-5700.
PMID: 35358392 PMC: 9014856. DOI: 10.1021/acs.jmedchem.1c02209.
Obata H, Tsuji A, Sudo H, Sugyo A, Minegishi K, Nagatsu K Int J Mol Sci. 2021; 22(9).
PMID: 33924843 PMC: 8124180. DOI: 10.3390/ijms22094622.
Synthesis of no-carrier-added [Pt]cisplatin from a cyclotron produced PtCl complex.
Obata H, Minegishi K, Nagatsu K, Ogawa M, Zhang M Sci Rep. 2021; 11(1):8140.
PMID: 33854142 PMC: 8046966. DOI: 10.1038/s41598-021-87576-2.
Alzheimer's Disease - Future Therapy Based on Dendrimers.
Aliev G, Ashraf G, Tarasov V, Chubarev V, Leszek J, Gasiorowski K Curr Neuropharmacol. 2018; 17(3):288-294.
PMID: 30227819 PMC: 6425077. DOI: 10.2174/1570159X16666180918164623.
Ghoreishi S, Khalaj A, Sabzevari O, Badrzadeh L, Mohammadzadeh P, Mousavi Motlagh S Int J Nanomedicine. 2018; 13:4671-4683.
PMID: 30154653 PMC: 6103604. DOI: 10.2147/IJN.S157426.